Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
Delayed Quote. Delayed Nasdaq - 01/18 04:00:01 pm
98.44 USD   -11.17%
01/18Gates, Wellcome pledge $150 mln each to pandemic preparedness group
RE
01/14COVID still a serious threat, warn German health officials
RE
01/14Top Premarket Decliners
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

India allows export of 20 mln Novavax vaccine doses to Indonesia -document, source

11/18/2021 | 02:26pm EST

NEW DELHI, Nov 19 (Reuters) - India has approved the export of 20 million doses of the Novavax COVID-19 vaccine made by the Serum Institute of India (SII) to Indonesia, according to a government document seen by Reuters and a government source.

The government has also decided to allow the export of 10 million doses of a licensed version of the AstraZeneca shot made by SII, which it calls Covishield, to the global vaccine-sharing programme COVAX, two sources said. Shipment is likely to happen towards the end of next month, one of the sources said.

SII and the health ministry could not be contacted early on Friday. (Reporting by Krishna N. Das Editing by Nick Zieminski)


ę Reuters 2021
All news about NOVAVAX, INC.
01/18Gates, Wellcome pledge $150 mln each to pandemic preparedness group
RE
01/14COVID still a serious threat, warn German health officials
RE
01/14Top Premarket Decliners
MT
01/13South Korea to deploy Pfizer COVID-19 pills as Omicron wave looms
RE
01/12South Korean Regulator Approves Novavax COVID-19 Vaccine
MT
01/12GLOBAL MARKETS LIVE : Boeing, J Sainsbury, Exxon Mobil, Sony, Apple...
01/12Today on Wall Street: Powell worked its magic
01/12Novavax COVID-19 Vaccine Secures Clearance In South Korea
MT
01/12South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine
PR
01/12South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine
CI
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Financials (USD)
Sales 2021 1 378 M - -
Net income 2021 -919 M - -
Net cash 2021 756 M - -
P/E ratio 2021 -8,00x
Yield 2021 -
Capitalization 7 443 M 7 443 M -
EV / Sales 2021 4,85x
EV / Sales 2022 1,33x
Nbr of Employees 792
Free-Float 98,5%
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | NVAX | US6700024010 | MarketScreener
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 98,44 $
Average target price 270,00 $
Spread / Average Target 174%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.-31.19%8 379
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%53 950
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684